Question · Q1 2026
Mackenzie inquired about the nature and timing of the strategic investments made in the quarter, and asked for a breakdown of the $25 million in Fiscal 2025 AI-driven orders, specifically how much came in Q4 and what was seen in Q1.
Answer
Emily Leproust, CEO and Co-Founder of Twist Bioscience, clarified that the $25 million in AI-driven orders from FY25 were backloaded, contributing to both Q4 and Q1 performance, with high confidence in repeat orders. She categorized investments into structural (e.g., hiring sales/commercial staff ahead of growth) and transient (e.g., improving digital infrastructure, like the new NGS e-commerce platform), emphasizing these investments are made without jeopardizing Q4 Adjusted EBITDA break-even.
Ask follow-up questions
Fintool can predict
TWST's earnings beat/miss a week before the call